6.02
0.25 (4.25%)
| Previous Close | 5.77 |
| Open | 5.88 |
| Volume | 474,127 |
| Avg. Volume (3M) | 757,722 |
| Market Cap | 233,508,912 |
| Price / Sales | 1.91 |
| Price / Book | 0.820 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Profit Margin | -35.28% |
| Operating Margin (TTM) | -86.92% |
| Diluted EPS (TTM) | -1.24 |
| Quarterly Revenue Growth (YOY) | -5.40% |
| Total Debt/Equity (MRQ) | 11.51% |
| Current Ratio (MRQ) | 8.29 |
| Operating Cash Flow (TTM) | -28.89 M |
| Levered Free Cash Flow (TTM) | -6.46 M |
| Return on Assets (TTM) | -9.38% |
| Return on Equity (TTM) | -14.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Mixed |
| Medical Devices (Global) | Bearish | Bearish | |
| Stock | Quanterix Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | -1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 2.0 |
| Average | 1.10 |
|
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 7.66% |
| % Held by Institutions | 89.70% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Easterly Investment Partners Llc | 31 Dec 2024 | 954,995 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 12.00 (Canaccord Genuity, 99.50%) | Buy |
| Median | 10.00 (66.25%) | |
| Low | 8.00 (Leerink Partners, 33.00%) | Hold |
| Average | 10.00 (66.25%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 5.20 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 13 May 2025 | 12.00 (99.50%) | Buy | 4.64 |
| Leerink Partners | 30 Apr 2025 | 8.00 (33.00%) | Hold | 5.76 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |